Deuterated Oxysterols for NMDA Modulation and Pharmacokinetics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oxysterols lack improved in vivo potency, pharmacokinetic properties, oral bioavailability, formulatability, stability, and safety for modulating NMDA receptor function, which are essential for treating NMDA-mediated disorders.
Innovation Solution
Development of substituted oxysterols, including deuterium-enriched compounds, to enhance potency and safety, with specific formulations for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional oxysterols are used to modulate NMDA receptor function, then some therapeutic effect is achieved, but in vivo potency and pharmacokinetic properties are insufficient
Solution Approach 1:
The patent modifies the chemical structure of oxysterols by changing parameters such as substituting hydrogen atoms with deuterium at specific positions (R1, R2, R3, R4, or R5 in the steroid nucleus), altering alkyl chain lengths (C1-6 alkyl groups), and modifying the configuration at chiral centers. These parameter changes result in compounds with improved in vivo potency and pharmacokinetic properties while maintaining NMDA receptor modulation activity.
2Reliability
If conventional oxysterols are used for NMDA-mediated disorders, then treatment is provided, but oral bioavailability and safety are limited
Solution Approach 1:
The patent employs parameter changes including deuterium substitution at specific positions in the steroid nucleus, modification of side chain structures (R1-R5 groups), and adjustment of molecular weight and lipophilicity. These changes enhance oral bioavailability by improving absorption, distribution, and metabolic stability, while also improving safety profiles by reducing off-target effects and toxicity.
Solution Approach 2:
The patent creates deuterated versions of conventional oxysterols by replacing hydrogen atoms with deuterium at specific positions. This copying approach with isotopic substitution maintains the basic pharmacological activity while improving pharmacokinetic properties and safety, as the deuterated compounds follow similar mechanisms of action but with enhanced metabolic stability and reduced clearance.
3Reliability
If existing oxysterol structures are used, then NMDA receptor modulation is achieved, but formulation and stability are inadequate
Solution Approach 1:
The patent modifies structural parameters of oxysterols by introducing deuterium atoms at specific positions (R1-R5), altering alkyl chain lengths and compositions (C1-6 alkyl or haloalkyl groups), and adjusting the configuration at chiral centers. These parameter changes improve stability by reducing metabolic degradation and enhancing formulation capabilities by optimizing solubility, bioavailability, and compatibility with different delivery systems.
Data Source
AI summary
Compounds are provided according to Formula (III):and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R5, and n are as defined herein, and at least one hydrogen is replaced with a deuterium. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.